Viridian Therapeutics, Inc.\DE

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

VRDN$30.86+2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share data)

Convertible Preferred Stock · Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Series A · Series B
Shares · Amount · Shares · Amount · Shares · Amount
Balance as of December 31, 2024	134,864		$61,188		145,160		$127,697		80,994,046			$810			$1,477,811			$(10)			$(995,857)			$671,639
Issuance of common stock, September 2022 ATM, net of issuance costs of $149	—		—		—		—		245,388		3			4,792			—			—			4,795
Issuance of common stock upon exercises of warrants	—		—		—		—		115,146			1			1,617			—			—			1,618
Issuance of common stock upon exercises of stock options	—		—		—		—		185,426			2			2,295			—			—			2,297
Issuance of common stock under employee stock purchase plan	—		—		—		—		41,106			—			561			—			—			561
Issuance of common stock upon vesting of restricted stock units	—	—		—		—		8,315		—			—			—			—			—
Share-based compensation expense	—		—		—		—		—			—			10,220			—			—			10,220
Unrealized gain on available-for-sale securities	—		—		—		—		—			—			—			255			—			255
Net loss	—		—		—		—		—			—			—			—			(86,912)			(86,912)
Balance as of March 31, 2025	134,864		$61,188		145,160		$127,697		81,589,427			$816			$1,497,296			$245			$(1,082,769)			$604,473
Issuance of common stock upon exercises of stock options	—		—		—		—		61,527			1			762			—			—			763
Issuance of common stock upon vesting of restricted stock units	—		—		—		—		232			—			—			—			—			—
Share-based compensation expense	—		—		—		—		—			—			10,844			—			—			10,844
Unrealized loss on available-for-sale securities	—		—		—		—		—			—			—			(176)			—			(176)
Net loss	—		—		—		—		—			—			—			—			(100,735)			(100,735)
Balance as of June 30, 2025	134,864		$61,188		145,160		$127,697		81,651,186			$817			$1,508,902			$69			$(1,183,504)			$515,169
Issuance of common stock, March 2025 ATM, net of issuance costs of $209	—	—		—		—		500,000		5			9,746			—			—			9,751
Issuance of common stock upon exercises of stock options	—	—		—		—		34,522		—			547			—			—			547
Issuance of common stock under employee stock purchase plan	—	—		—		—		43,450		—			558			—			—			558
Share-based compensation expense	—	—		—		—		—		—			11,250			—			—			11,250
Unrealized gain on available-for-sale securities	—	—		—		—		—		—			—			294			—			294
Net loss	—	—		—		—		—		—			—			—			(34,599)			(34,599)
Balance as of September 30, 2025	134,864		$61,188		145,160		$127,697		82,229,158			$822			$1,531,003			$363			$(1,218,103)			$502,970

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share data)

Convertible Preferred Stock · Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Series A · Series B
Shares · Amount · Shares · Amount · Shares · Amount
Balance as of December 31, 2023	172,435	$78,235	143,522		$128,281		53,986,112	$540		$960,536		$338		$(725,908)		$442,022
Issuance of common stock upon the conversion of convertible preferred stock	(15,000)	(6,806)	—		—		1,000,048		10		6,796		—		—		—
Issuance of common stock, January 2024 Public Offering, net of issuance costs of $9,304	—	—	—		—		7,142,858		71		140,625		—		—		140,696
Issuance of common stock, September 2022 ATM, net of issuance costs of $1,088	—	—	—		—		1,561,570		15		35,162		—		—		35,177
Issuance of common stock for exercises of stock options	—	—	—		—		66,191		1		837		—		—		838
Issuance of common stock for cash under employee stock purchase plan	—	—	—		—		22,642		—		356		—		—		356
Vesting of restricted stock units	—	—	—		—		19,115		1		(1)		—		—		—
Share-based compensation expense	—	—	—		—		—		—		12,688		—		—		12,688
Change in unrealized loss on investments	—	—	—		—		—		—		—		(705)		—		(705)
Net loss	—	—	—		—		—		—		—		—		(48,542)		(48,542)
Balance as of March 31, 2024	157,435	$71,429	143,522		$128,281		63,798,536		$638		$1,156,999		$(367)		$(774,450)		$582,530
Issuance of common stock for exercises of stock options	—	—	—		—		81,139		1		209		—		—		210
Share-based compensation expense	—	—	—		—		—		—		11,767		—		—		11,767
Change in unrealized loss on investments	—	—	—		—		—		—		—		(176)		—		(176)
Net loss	—	—	—		—		—		—		—		—		(64,993)		(64,993)
Balance as of June 30, 2024	157,435	$71,429	143,522		$128,281		63,879,675		$639		$1,168,975		$(543)		$(839,443)		$529,338
Issuance of common stock upon the conversion of convertible preferred stock	(22,571)	(10,241)	(18,362)		(24,085)		2,729,000		27		34,299		—		—		—
Issuance of Series B preferred stock and common stock, September 2024 Public Offering, net of issuance costs of $15,524	—	—	20,000		23,501		12,466,600		125		219,600		—		—		243,226
Issuance of common stock for exercises of stock options	—	—	—		—		84,676		1		1,108		—		—		1,109
Issuance of common stock for cash under employee stock purchase plan				21,494		—		317		—		—		317
Share-based compensation expense	—	—	—		—		—		—		8,720		—		—		8,720
Change in unrealized gain on investments	—	—	—		—		—		—		—		1,475		—		1,475
Net loss	—	—	—		—		—		—		—		—		(76,689)		(76,689)
Balance as of September 30, 2024	134,864	$61,188	145,160		$127,697		79,181,445		$792		$1,433,019		$932		$(916,132)		$707,496

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.